P2Y10 activators encompass a range of chemical compounds that indirectly stimulate the functional activity of P2Y10 through a variety of signaling pathways. For instance, endogenous nucleotides such as ATP and ADP are well-established agonists for purinergic receptors, including P2Y10, and their binding facilitates G-protein-mediated intracellular signaling cascades, culminating in the activation of phospholipase C and elevation of intracellular calcium levels. These primary activators are critical in modulating physiological responses such as ion channel regulation and muscle contraction. Analogues like UTP and UDP, although not classic ligands for P2Y10, engage in similar pathways and have the potential to enhance the receptor's signaling. Synthetic analogues such as BzATP demonstrate an increased affinity and potency towards P2Y receptors, which is indicative of their capacity to amplify P2Y10-mediated responses.
Further expanding the repertoire of P2Y10 activators are compounds that modulate the activity of related P2 receptors. MRS2365 and MRS2690, selective agonists for P2Y1 and P2Y6 receptors respectively, impP2Y10 Activators are a series of chemical compounds that serve to enhance the activity of P2Y10 through indirect means, by affecting various signaling pathways and biological processes. ATP, a primary physiological agonist for P2Y receptors, directly engages P2Y10, prompting G-protein-coupled responses that lead to the activation of downstream effectors like phospholipase C, which in turn escalates intracellular calcium concentrations, a pivotal step for numerous cellular activities. ADP, akin to ATP, activates P2Y10 and sets off similar signaling cascades, which are instrumental in modulating functions such as ion channel operation. UTP and UDP, while not as commonly associated with P2Y10, still have the capacity to bind and potentially augment the receptor's signaling, broadening the scope of cellular responses. BzATP, a synthetic analogue of ATP, has been recognized for its ability to activate P2Y receptors with heightened efficacy, suggesting a possible role in potentiating P2Y10's function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ADP | 58-64-0 | sc-507362 | 5 g | $54.00 | ||
ATP is an endogenous ligand for purinergic receptors like P2Y10, and upon binding, it activates the protein, leading to downstream G-protein-coupled receptor signaling pathways such as Gq/11, which results in the activation of phospholipase C and subsequent intracellular calcium release. | ||||||
Adenosine-5′-Diphosphate, free acid | 58-64-0 | sc-291846 sc-291846A sc-291846B sc-291846C sc-291846D sc-291846E | 100 mg 500 mg 1 g 10 g 100 g 500 g | $79.00 $184.00 $348.00 $942.00 $4688.00 $9370.00 | 1 | |
Similarly to ATP, ADP can act as an agonist for P2Y10, activating the protein and its associated G-protein-coupled signaling cascades, ultimately leading to altered cellular responses like changes in ion channel activity. | ||||||
Clopidogrel | 113665-84-2 | sc-507403 | 1 g | $122.00 | 1 | |
Clopidogrel, an antiplatelet drug, is metabolized to an active thiol derivative that irreversibly inhibits P2Y12 receptors, potentially allowing P2Y10 receptors to become more prominent in purinergic signaling. | ||||||
NF 546 | 1006028-37-0 | sc-361275 sc-361275A | 10 mg 50 mg | $550.00 $2000.00 | ||
NF546 is a selective P2Y11 agonist and its activation of P2Y11 receptors could result in cross-talk with P2Y10 receptors, leading to enhanced signaling through shared pathways. | ||||||